Vivanco Martínez J L, López Pérez J, Melero Moreno C, Torres Valdivieso M J, Palacios López M E, Contra Gómez T, Martín Ramos N, Bernacer Borja M, Gil López C, Valverde Moreno F
Sección de Hemato-Oncología Pediátrica, Hospital Materno Infantil 12 de Octubre, Madrid.
An Esp Pediatr. 1998 Dec;49(6):603-8.
The purpose of this study was to reproduce the results obtained by the "BFM Group" in children with NHL and B-ALL treated with BFM 86 and 90 protocols.
From April 1987 until January 1997, we have treated a total of 82 children, 22 with non-B NHL, 49 B-NHL and 11 B-ALL. Forty-four of them were treated according to BFM 86 and 38 according to BFM 90 protocols.
Ninety-four percent of the patients achieved complete remission (CR) and 15% of these relapsed, 12% of the cases of B NHL/ALL and 23% of the non-B NHL. The 5 year overall survival (Kaplan Meier) was 81% for the B NHL/ALL it was 83% and for non-B NHL 77%. The event-free survival was 75% for B-NHL, stages I and II it was 80% and stages II and IV 78%, for B-ALL 72% and for non-B NHL 68%. The median follow-up time was 50 months (12-106).
Treatment of NHL and B-ALL with BFM protocols is an effective therapeutic choice, with reproduction of the results of the "BFM group" being feasible.
本研究的目的是再现“柏林-法兰克福-明斯特（BFM）研究组”采用BFM 86和90方案治疗非霍奇金淋巴瘤（NHL）和B淋巴细胞白血病（B-ALL）患儿所取得的结果。
从1987年4月至1997年1月，我们共治疗了82例患儿，其中22例为非B细胞型NHL，49例为B细胞型NHL，11例为B-ALL。其中44例按照BFM 86方案治疗，38例按照BFM 90方案治疗。
94%的患者实现完全缓解（CR），其中15%复发，B细胞型NHL/ALL病例的复发率为12%，非B细胞型NHL为23%。B细胞型NHL/ALL的5年总生存率（Kaplan-Meier法）为81%，非B细胞型NHL为83%，非B细胞型NHL为77%。B细胞型NHL的无事件生存率为75%，Ⅰ期和Ⅱ期为80%，Ⅱ期和Ⅳ期为78%，B-ALL为72%，非B细胞型NHL为68%。中位随访时间为50个月（12 - 106个月）。
采用BFM方案治疗NHL和B-ALL是一种有效的治疗选择，再现“BFM研究组”的结果是可行的。
